Substituted Quinolone Carboxylic Acids, Their Derivatives, Site of Action, And Uses Thereof

Abstract

Substituted quinolone carboxylic acids and their derivatives are described. These compounds modulate the effect of γ-aminobutyric acid (GABA) via a novel site on the GABA A receptor complex in a therapeutically relevant fashion and may be used to ameliorate CNS disorders amenable to modulation of the GABA A receptor complex.

1 - 13 . (canceled) 
     
     
         14 . A method for the treatment of CNS disorders amenable to amelioration via modulation of the GABA A  receptor complex, comprising the step of: administering to a patient in need of such treatment an effective amount of compound of Formula I: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:
 R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl, and aralkyl; 
 each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
 each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl; a group OR 11  and NR 12 R 13 ; 
 R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen; 
 R 9  and R 10  are independently selected from the group consisting of optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
 R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
 R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring. 
 
     
     
         15 . The method of  claim 14 , wherein the compound comprises a compound having the Formula II: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:
 R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl, and aralkyl; 
 each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
 R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen; 
 R 9  and R 10  are independently selected from the group consisting of optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring. 
 
     
     
         16 . The method of  claim 14 , wherein the compound comprises a compound having the Formula III: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: R 1 , R 2 , R 5 , R 7 , R 8 , R 9  are as defined in claim  1 ; n is an integer 0, 1, 2, 3 or 4. 
     
     
         17 . The method of  claim 16 , wherein n is 2. 
     
     
         18 . The method of  claim 16 , wherein R 1  is alkyl, R 2 , R 5  and R 8  are hydrogen and R 7  is halogen. 
     
     
         19 . The method of  claim 14 , wherein the compound is: 7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro (phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         20 . A method for the treatment of anxiety and related disorders, which comprises administering to a patient in need of such treatment an effective amount of a compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl; a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl and halogen; 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, aryl, cycloalkyl and cycloaralkyl, or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         21 . A method for the treatment of convulsions, which comprises administering to a patient in need of such treatment an effective amount of a compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl, and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl; a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen; 
         R 9  and R 10  are independently selected from the group consisting of hydrogen optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         22 . A method for the treatment of insomnia, which comprises administering to a patient in need of such treatment an effective amount of compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl, and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl, a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen; 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         23 . A method for the treatment of major depressive and bipolar disorders, which comprises administering to a patient in need of such treatment an effective amount of compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl; a group OR 11  and NR 12 R 13 . 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl and halogen; 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         24 . A method for the treatment of chronic or acute pain, which comprises administering to a patient in need of such treatment an effective amount of compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl, and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl; a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen; 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         25 . A method for the treatment of neuroses, which comprises administering to a patient in need of such treatment an effective amount of compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl, and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl; a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen; 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         26 . A method for the treatment of withdrawal-induced convulsions from substance abuse which comprises administering to a patient in need of such treatment an effective amount of compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl, and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl; a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen; 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, aryl, cycloalkyl and cycloaralkyl, or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are, H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         27 . A method for the treatment of phobias, which comprises administering to a patient in need of such treatment an effective amount of compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl, and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl; a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen; 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         28 . A method for the treatment of panic disorders, which comprises administering to a patient in need of such treatment an effective amount of compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl, and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl, a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen; 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl, 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         29 . A method for the treatment of generalized anxiety disorders which comprises administering to a patient in need of such treatment an effective amount of compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl, and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl; a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen; 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         30 . A method for the treatment of obsessive-compulsive disorders which comprises administering to a patient in need of such treatment an effective amount of compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl, and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl; a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen; 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl: 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         31 . A method for the treatment of post traumatic and acute stress disorders, which comprises administering to a patient in need of such treatment an effective amount of compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen, an optionally substituted alkyl, and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen; 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         32 . A method for the treatment of migraine pain, which comprises administering to a patient in need of such treatment an effective amount of compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen, an optionally substituted alkyl, and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl, a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen; 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl aralkyl, aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         33 . A method for the treatment of bipolar manic disorders, which comprises administering to a patient in need of such treatment an effective amount of compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl, and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl; a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen; 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl aralkyl, aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         34 . A method for the treatment of cognition deficit disorders, which comprises administering to a patient in need of such treatment an effective amount of compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl, and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen, 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , —R 11  is H, R 5  and R 8  are H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         35 . A method for the treatment of disorders such as anxiety and stress related disorders, depression and other affective disorders, epilepsy and other seizure disorders, insomnia and related sleep disorders, and acute and chronic pain by enhancement of chloride conductance through the site mediating the action of compound of Formula I 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen, an optionally substituted alkyl, and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl; a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen; 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are H, then R 1  is not Et, with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         36 . A method for the treatment of disorders related to learning and memory such as mild cognitive impairment, age related cognitive decline, senile dementia, Alzheimer's disease, sleep disorders involving reduced wakefulness such as narcolepsy and idiopathic hypersomnia by inhibition of chloride conductance through the site mediating the action of compound of Formula I 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen; an optionally substituted alkyl, and aralkyl; 
         each R 2  is selected from the group consisting of hydrogen and optionally substituted alkyl; 
         each R 3  is selected from the group consisting of hydrogen, optionally substituted alkyl: a group OR 11  and NR 12 R 13 ; 
         R 5 , R 7  and R 8  are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, and halogen, 
         R 9  and R 10  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, cycloalkyl and cycloaralkyl; or R 9  and R 10  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
         R 11  is selected from the group consisting of hydrogen, an alkali metal, a negative charge and optionally substituted alkyl; 
         R 12  and R 13  are independently selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, aryl, cycloalkyl and cycloaralkyl; or R 12  and R 13  are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; 
       
       with the proviso that when R 9  and R 10  are taken together to form a piperazinyl ring, R 7  is Cl, R 3  is OR 11 , R 11  is H, R 5  and R 8  are H, then R 1  is not Et; with the further proviso that when R 9  and R 10  taken together to form 4-methylpiperazine, R 7  is Cl, R 3  is OR 11 , R 11  is H, and R 5  and R 8  are H, then R 1  is not Et; and with the further proviso that when R 9  and R 10  are taken together to form a morpholinyl ring, R 1 , R 2 , R 5 , R 7 , R 8  are H, R 3  is NR 12 R 13  and either R 12  or R 13  is H, the other is not n-butyl. 
     
     
         37 . The method of  claim 20  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         38 . The method of  claim 21  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         39 . The method of  claim 22  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         40 . The method of  claim 23  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         41 . The method of  claim 24  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         42 . The method of  claim 25  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         43 . The method of  claim 26  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         44 . The method of  claim 27  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         45 . The method of  claim 28  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         46 . The method of  claim 29  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         47 . The method of  claim 30  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         48 . The method of  claim 31  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         49 . The method of  claim 32  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         50 . The method of  claim 33  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         51 . The method of  claim 34  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         52 . The method of  claim 35  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof. 
     
     
         53 . The method of  claim 36  wherein the compound is 7-Chloro-1-ethyl-6-1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-7-Chloro-1-ethyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(1-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-aminoindanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(benzylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(phenethyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[3-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[2-methoxy(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-bromo(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-[4-chloro(phenethylamino)]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(3-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(4-phenylbutyl-2-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenylpropylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-Chloro-1-ethyl-6-(2-phenoxyethylamino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or 7-Chloro-1-methyl-6-(1,2,3,4-tetrahydronaphthyl-1-amino)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; or a pharmaceutically acceptable salt, prodrug or solvate thereof.